January 13, 2021

EVOQ Therapeutics Announces a License and Collaboration Agreement with Amgen

ANN ARBOR, Mich., January 13, 2021 /PRNewswire/ -- EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes both innovative medicines, including Otezla® and Enbrel®, and biosimilar products, such as AMGEVITA® (a biosimilar to Humira®) and AVSOLA® (a biosimilar to Remicade®).

About EVOQ Therapeutics


EVOQ Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens for recognition by the immune system. 

November 14, 2019

Accelerate Michigan Innovation Competition Announces EVOQ Therapeutics as Grand Prize Recipient

Accelerate Michigan Innovation Competition (AMIC), a program of Invest Detroit’s ID Ventures, today announced EVOQ Therapeutics was selected as the grand prize recipient at the tenth annual pitch competition. The pitch competition celebrated the 10 year anniversary of the pitching competition, which provides critical funding and support for Michigan startups.


“We are thrilled to celebrate the 10 year anniversary of AMIC,” said Martin Dober, senior vice president and managing director of ID Ventures. “This significant milestone highlights the dedication of Michigan’s entrepreneurial ecosystem to fueling the growth of startups. With their support, startups have been able to receive the critical funding and support they need to build innovative, high-tech companies in the state.”


ID Ventures and its top sponsors Ralph C. Wilson, Jr. Foundation, Invest Michigan, William Davidson Foundation, Michigan Economic Development Corporation and Belle Michigan Impact Fund, among other corporate and startup leaders across Michigan, awarded nearly $1 million in cash to eight innovative startups that were selected from 24 semi-finalists. Nearly 400 top investors, entrepreneurs and community leaders attended the event at the State Savings Bank in Detroit, MI.


Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs

Hassani Najafabadi A, Zhang J, Aikins ME, Najaf Abadi ZI, Liao F, Qin Y, Okeke EB, Scheetz LM, Nam J, Xu Y, Adams D, Lester P, Hetrick T, Schwendeman A, Wicha MS, Chang AE, Li Q, and Moon JJ. 

Nano Letters, 2020

Robust Anti‐Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy

Kuai R, Singh PB, Sun X, Xu C, Najafabadi Hassani A, Scheetz L, Yuan W, Xu Y, Hong H, Keskin DB, Wu CJ, Jain R, Schwendeman A, and Moon JJ

Advanced Therapeutics. doi: 10.1002/adtp.202000094, 2020

Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas

Scheetz L, Kadiyala P, Sun X, Son S, Najafabadi AH, Aikins, M, Lowenstein PR, Schwendeman A, Castro MG, and Moon JJ 

Clinical Cancer Research, doi: 10.1158/1078-0432.CCR-20-0341, 2020

High-Density Lipoprotein-Mimicking NanoDiscs for Chemo-immunotherapy against Glioblastoma Multiforma

Padma Kadiyala, Dan Li, Fernando M. Nuñez, David Altshuler, Robert Doherty, Rui Kuai, Minzhi Yu, Neha Kamran,  Marta Edwards, James J. Moon, Pedro R. Lowenstein, Maria G. Castro, Anna Schwendeman

ACS NANO 2019, 13, 1365-1384

Cancer Nanomedicine for Combination Cancer Immunotherapy

Jutaek Nam, Sejin Son, Kyung Soo Park, Weiping Zou, Lonnie D. Shea, and James J. Moon

Nature Reviews Materials. Vol. 4, 398-414, June 2019

Engineering Patient-Specific Cancer Immunotherapies

Lindsay Scheetz, Kyung Soo Park, Qiao Li, Pedro R. Lowenstein, Maria G. Castro, Anna Schwendeman, and

James J. Moon

Nature Biomedical Engineering August 2019

Elimination of Established Tumors with Nanodisc-based Combination Chemoimmunotherapy

Kuai R, Yuan W, Son S, Nam J, Xu Y, Fan Y, Schwendeman A, and Moon JJ

Science Advances. 4, eaao1736, 2018

Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy

Kuai R, Sun X, Yuan W, Xu Y, Schwendeman A and Moon JJ

Bioconjugate Chemistry. 29 (3), 771-775, 2018

Designer Vaccine Nanodiscs for Personalized Cancer Immunotherapy

Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A and Moon JJ

Nature Materials. 16 (4), 489-496, 2017

High-density Lipoproteins: Nature’s Multifunctional Nanoparticles

Kuai R, Li D, Chen YE, Moon JJ, and Schwendeman A

ACS NANO. 10, 3, 3015-41, 2016

Lipid-Based Nanoparticles Vaccine Applications

Kuai R, Ochyl LJ, Schwendeman A, and Moon JJ

Biomedical Engineering: Frontier Research and Converging Technologies, Springer, Edited by Drs. Jo, Jun, Shin, and Lee. 9, 177-197, 2015